MultiCell Technologies Inc.'s (MUCL) Xenogenics Subsidiary Granted Artificial Liver Device Patent; Sybiol Device Offers Potential To Treat Millions Of Patients With Liver Trauma Or Insufficiency
10/19/2005 5:12:49 PM
WARWICK, R.I.--(BUSINESS WIRE)--Feb. 24, 2005--MultiCell Technologies, Inc. (MultiCell): (OTCBB: MUCL) announced today that its majority owned subsidiary, Xenogenics Corporation ("Xenogenics"), has been granted U.S. patent 6,858,146 on its Sybiol(R) synthetic bio-liver device. The '146 patent includes over 40 claims to the device and methods for its use in the purification of a patient's bodily fluids.
"This long-awaited patent offers the hope of helping many millions of people with liver trauma or insufficiency around the world," said Jerry Newmin, MultiCell's CEO. "The company intends to file additional patents covering further improvements to the Sybiol device and its application."
comments powered by